Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗,以及既往接受过或不适合接受抗血管内皮生长因子(VEGF)治疗、抗表皮生长因子受体(EGFR)治疗(RAS野生型)的转移性结直肠癌(mCRC)患者。
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.